Patent intelligence · CA
CA 2852397
UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII
UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII
Patent details — CA 2852397
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Apr 25, 2013
- Expiration
- Apr 20, 2033
- Applicant
- CSL BEHRING GMBH [DE]
- CPC classes
- A61K 38/ 36 A I, A61K 38/ 37 A I, A61K 47/ 36 A I, A61K 47/ 42 A I
Quick answer
CA 2852397 (UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII) is held by CSL BEHRING GMBH [DE]. Status: granted. Granted Apr 25, 2013. Expires Apr 20, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CSL BEHRING GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 36 A I, A61K 38/ 37 A I, A61K 47/ 36 A I, A61K 47/ 42 A I, A61K/3837, A61K/4736
More from CSL BEHRING GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2022258590
PROCÉDÉ D'ISOLEMENT DE PLASMINOGÈNE À PARTIR D'UNE FRACTION DE PLASMA SANGUIN
granted -
CA 3198740
METHODES DE TRAITEMENT D'UN REJET A MEDIATION PAR ANTICORPS
granted -
AU 2017305856
Pharmaceutical formulations of C1 esterase inhibitor
granted -
DK 2928905
FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER
granted -
CA 3072003
PROCEDE DE FILTRATION VIRALE DU FACTEUR DE VON WILLEBRAND
granted -
US 2018264111
PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS
granted -
CA 3046406
PRODUIT DE REMPLACEMENT DE FACTEUR DE COAGULATION SANGUINE POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THERAPEUTIQUE DES HEMORRAGIES
granted -
CA 3034568
PROCEDE DE PREVENTION D'ATTAQUES AIGUES D'OEDEME DE QUINCKE HEREDITAIRE ASSOCIEES A UNE DEFICIENCE EN INHIBITEUR DE C1 ESTERASE
granted
Frequently asked questions
What is US patent 2852397?
CA 2852397 (UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII) is held by CSL BEHRING GMBH [DE]. Status: granted. Granted Apr 25, 2013. Expires Apr 20, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2852397?
CSL BEHRING GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 2852397 expire?
Our index shows an expiration date of Apr 20, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.